| Keyword | CPC | PCC | Volume | Score | Length of keyword |
|---|---|---|---|---|---|
| dupixent and asthma approval | 1.74 | 0.8 | 4792 | 95 | 28 |
| dupixent | 0.75 | 1 | 4045 | 46 | 8 |
| and | 0.83 | 0.1 | 3959 | 5 | 3 |
| asthma | 0.46 | 1 | 6237 | 10 | 6 |
| approval | 0.06 | 0.3 | 9097 | 46 | 8 |
| Keyword | CPC | PCC | Volume | Score |
|---|---|---|---|---|
| dupixent and asthma approval | 1.9 | 0.6 | 5922 | 13 |
| dupixent asthma approval | 1.77 | 0.7 | 8799 | 30 |
| fda approval dupixent asthma | 0.66 | 0.3 | 6559 | 23 |
| dupixent pediatric asthma ema approval | 1.93 | 0.7 | 5872 | 87 |
DUPIXENT helps prevent severe asthma attacks (exacerbations) and can improve your breathing. DUPIXENT may also help reduce the amount of oral corticosteroids you need while preventing severe asthma attacks and improving your breathing. DUPIXENT is not used to treat sudden breathing problems.
What is Dupixent approved for?“Dupixent is the first biologic to be approved for the treatment of chronic rhinosinusitis with nasal polyposis, beating rivals in gaining market approval and first-to-market advantage.
When was DUPIXENT approved?May 26, 2020 Morgan Petronelli, Associate Editor The U.S. FDA has approved dupilumab (Dupixent, Sanofi and Regeneron) for the treatment of atopic dermatitis in children 6-11 years, making it the first biologic approved for atopic dermatitis in this particular age group.
When was Dupixent FDA approved?FDA Approves New Dupixent (dupilumab) Pre-Filled Pen Designed to Support More Convenient Self-Administration - June 19, 2020; FDA Approves Dupixent (dupilumab) as First Biologic Medicine for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis - May 26, 2020
